C4 Therapeutics, INC Form 4 insider transactions

C4 Therapeutics, Inc. Director Steven L. Hoerter was granted 35,500 stock options with an exercise price of $1.44 per share, as disclosed in a recent SEC Form 4 filing.

Director Donna Grogan acquired 9,581 shares of C4 Therapeutics common stock in lieu of cash compensation, while disposing of 42,280 shares.

Director Kenneth Anderson acquired 7,841 shares of C4 Therapeutics common stock in lieu of cash compensation, according to a recent SEC filing.

Andrew Hirsch, CEO of C4 Therapeutics, reports acquisition of restricted stock units and stock options, as well as shares withheld for tax obligations.

Jolie Siegel, Chief Legal Officer of C4 Therapeutics, reports acquisition and disposal of common stock and stock options.

Scott N. Boyle, Chief Business Officer of C4 Therapeutics, reports acquisition and disposal of common stock and stock options.

Mark Mossler, Chief Accounting Officer of C4 Therapeutics, reports the withholding of shares to cover tax obligations related to vested restricted stock units.

Kelly Schick, Chief People Officer at C4 Therapeutics, reports acquisition and disposal of common stock and stock options.

C4 Therapeutics' Chief Financial Officer, Kendra Adams, reports acquisition and disposal of company stock and stock options.

Paige Mahaney, Chief Scientific Officer of C4 Therapeutics, reports acquisition of restricted stock units and stock options, along with disposal of common stock.

Chief Medical Officer Leonard Reyno reports transactions involving C4 Therapeutics common stock and stock options, including acquisition of restricted stock units and shares withheld for tax obligations.

Director Donna Grogan acquired 3,757 shares of C4 Therapeutics common stock in lieu of cash compensation, while disposing of 32,699 shares.

Director Kenneth Anderson acquired 3,074 shares of C4 Therapeutics common stock at $3.66 per share in lieu of cash compensation, according to a Form 4 filing.

Steven L. Hoerter, a director at C4 Therapeutics, acquired 65,000 stock options on November 19, 2024, which vest over time.

C4 Therapeutics' Chief Business Officer, Scott N. Boyle, exercised performance restricted stock units and sold shares to cover tax obligations on November 7, 2024.

Kendra Adams, CFO of C4 Therapeutics, reports the vesting of performance restricted stock units and shares withheld for tax obligations.

Kelly Schick, Chief People Officer at C4 Therapeutics, reports the vesting of performance restricted stock units and subsequent tax withholding.

Jolie Siegel, Chief Legal Officer of C4 Therapeutics, reports the vesting and tax withholding of performance restricted stock units.

C4 Therapeutics CEO Andrew Hirsch reports the vesting and settlement of performance restricted stock units (PRSUs) and shares withheld for tax obligations.

Paige Mahaney, Chief Scientific Officer of C4 Therapeutics, reports the acquisition of stock options and restricted stock units in the company.

Donna Roy Grogan, a director at C4 Therapeutics, acquired 2,474 shares of common stock in lieu of cash compensation on October 1, 2024.

Director Kenneth Carl Anderson acquired 2,023 shares of C4 Therapeutics common stock at $5.56 per share in lieu of cash compensation.

C4 Therapeutics' Chief Financial Officer, Kendra Adams, reports the withholding of shares to cover tax obligations related to vested restricted stock units.

Andrew Hirsch, CEO of C4 Therapeutics, reports the vesting and tax withholding of performance restricted stock units.

Scott N. Boyle, Chief Business Officer of C4 Therapeutics, exercised performance restricted stock units and disposed of shares to cover tax obligations on September 16, 2024.

C4 Therapeutics' Chief Financial Officer, Kendra Adams, reports the acquisition and disposal of company stock and performance restricted stock units.

Stewart Fisher, Chief Scientific Officer of C4 Therapeutics, reports the vesting of performance restricted stock units and shares withheld for tax obligations.

Kelly Schick, Chief People Officer at C4 Therapeutics, reports the vesting of performance restricted stock units and shares withheld for tax obligations.

Jolie Siegel, Chief Legal Officer of C4 Therapeutics, reports the vesting and tax withholding of performance restricted stock units.

Director Stephen Fawell acquired 65,000 stock options in C4 Therapeutics, Inc. on August 29, 2024.